KR20230123919A - Cdk 억제제 및 약제로서의 이의 용도 - Google Patents
Cdk 억제제 및 약제로서의 이의 용도 Download PDFInfo
- Publication number
- KR20230123919A KR20230123919A KR1020237013408A KR20237013408A KR20230123919A KR 20230123919 A KR20230123919 A KR 20230123919A KR 1020237013408 A KR1020237013408 A KR 1020237013408A KR 20237013408 A KR20237013408 A KR 20237013408A KR 20230123919 A KR20230123919 A KR 20230123919A
- Authority
- KR
- South Korea
- Prior art keywords
- pyridin
- formula
- fluoro
- pyrimidin
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081126P | 2020-09-21 | 2020-09-21 | |
| US63/081,126 | 2020-09-21 | ||
| US202163221959P | 2021-07-15 | 2021-07-15 | |
| US63/221,959 | 2021-07-15 | ||
| PCT/US2021/051226 WO2022061273A1 (en) | 2020-09-21 | 2021-09-21 | Cdk inhibitors and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230123919A true KR20230123919A (ko) | 2023-08-24 |
Family
ID=78087595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237013408A Pending KR20230123919A (ko) | 2020-09-21 | 2021-09-21 | Cdk 억제제 및 약제로서의 이의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11685744B2 (https=) |
| EP (1) | EP4214213A1 (https=) |
| JP (1) | JP2023543433A (https=) |
| KR (1) | KR20230123919A (https=) |
| CN (1) | CN116583283B (https=) |
| AU (1) | AU2021345423A1 (https=) |
| CA (1) | CA3196016A1 (https=) |
| IL (1) | IL301509B1 (https=) |
| MX (1) | MX2023003264A (https=) |
| WO (1) | WO2022061273A1 (https=) |
| ZA (1) | ZA202304541B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220079851A (ko) * | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
| EP4433059A4 (en) * | 2021-11-15 | 2025-06-18 | Erasca, Inc. | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE |
| US20250109140A1 (en) * | 2022-01-05 | 2025-04-03 | Remix Theraputics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| CA3245813A1 (en) * | 2022-03-23 | 2023-09-28 | Prelude Therapeutics, Incorporated | POLYMORPHIC COMPOUNDS AND THEIR USES |
| TW202400168A (zh) * | 2022-05-04 | 2024-01-01 | 美商艾瑞斯卡公司 | 噻吩ulk1/2抑制劑及其用途 |
| WO2024051717A1 (zh) * | 2022-09-08 | 2024-03-14 | 上海深势唯思科技有限责任公司 | 作为plk1抑制剂的化合物及其制备方法和用途 |
| WO2025128616A1 (en) * | 2023-12-12 | 2025-06-19 | Genesis Therapeutics, Inc. | Compounds for treating cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| JP2007501827A (ja) * | 2003-08-08 | 2007-02-01 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なピリミジルピロール誘導体 |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| WO2009040399A1 (en) * | 2007-09-28 | 2009-04-02 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| CA2908098A1 (en) | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN108779117B (zh) * | 2015-12-27 | 2021-08-31 | 重庆复创医药研究有限公司 | 一类激酶抑制剂 |
| WO2017133701A1 (en) * | 2016-02-06 | 2017-08-10 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
| EP3939986A1 (en) | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| US12133841B2 (en) | 2018-05-22 | 2024-11-05 | Js Innomed Holdings Ltd. | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
| CN112457326B (zh) * | 2019-09-06 | 2022-02-15 | 上海凌达生物医药有限公司 | 一类芳香杂环并内酰胺类化合物、制备方法和用途 |
-
2021
- 2021-09-21 US US17/480,323 patent/US11685744B2/en active Active
- 2021-09-21 AU AU2021345423A patent/AU2021345423A1/en active Pending
- 2021-09-21 MX MX2023003264A patent/MX2023003264A/es unknown
- 2021-09-21 CN CN202180077972.9A patent/CN116583283B/zh active Active
- 2021-09-21 WO PCT/US2021/051226 patent/WO2022061273A1/en not_active Ceased
- 2021-09-21 IL IL301509A patent/IL301509B1/en unknown
- 2021-09-21 CA CA3196016A patent/CA3196016A1/en active Pending
- 2021-09-21 JP JP2023518280A patent/JP2023543433A/ja active Pending
- 2021-09-21 EP EP21790738.5A patent/EP4214213A1/en active Pending
- 2021-09-21 KR KR1020237013408A patent/KR20230123919A/ko active Pending
-
2023
- 2023-03-16 US US18/185,193 patent/US20230357265A1/en active Pending
- 2023-04-19 ZA ZA2023/04541A patent/ZA202304541B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022061273A1 (en) | 2022-03-24 |
| US20230357265A1 (en) | 2023-11-09 |
| MX2023003264A (es) | 2023-06-06 |
| CN116583283B (zh) | 2026-03-17 |
| IL301509A (en) | 2023-05-01 |
| JP2023543433A (ja) | 2023-10-16 |
| AU2021345423A1 (en) | 2023-05-11 |
| CA3196016A1 (en) | 2022-03-24 |
| IL301509B1 (en) | 2026-01-01 |
| AU2021345423A9 (en) | 2024-10-24 |
| US11685744B2 (en) | 2023-06-27 |
| EP4214213A1 (en) | 2023-07-26 |
| CN116583283A (zh) | 2023-08-11 |
| ZA202304541B (en) | 2025-03-26 |
| US20220089608A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4417607A1 (en) | Heterocyclic compound as sos1 inhibitor and uses thereof | |
| US11685744B2 (en) | CDK inhibitors and their use as pharmaceuticals | |
| US12129262B2 (en) | CDK inhibitors and their use as pharmaceuticals | |
| KR20230117577A (ko) | Brm을 표적으로 하는 화합물 및 연관된 사용 방법 | |
| KR20220027879A (ko) | 질소 함유 헤테로사이클릭 유도체의 조절제, 이의 제조방법 및 용도 | |
| WO2024077216A1 (en) | Cdk inhibitors and their use as pharmaceuticals | |
| WO2023172957A1 (en) | Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals | |
| US20240246993A1 (en) | CDK Inhibitors And Their Use As Pharmaceuticals | |
| WO2023150612A1 (en) | Cdk inhibitors and their use as pharmaceuticals | |
| EA050130B1 (ru) | Ингибиторы cdk и их применение в качестве лекарственных препаратов | |
| US20240352029A1 (en) | CDK Inhibitors And Their Use As Pharmaceuticals | |
| WO2025240835A2 (en) | Jak2 inhibitors and their use as pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |